Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review

Lachaine Jean, Miron Audrey, Catherine Beauchemin, On Behalf Of The iGenoMed Consortium, Lachaine Jean, Miron Audrey, Catherine Beauchemin, On Behalf Of The iGenoMed Consortium

Abstract

Objective: The objective of this literature review was to evaluate the existing evidence regarding the cost-effectiveness of treatment options in IBD.

Methods: A systematic review of the literature was conducted to identify economic evaluations of IBD therapy. The literature search was performed using electronic databases MEDLINE and EMBASE. Searches were limited to full economic evaluations published in English or French between 2004 and 2016.

Results: A total of 5,403 potentially relevant studies were identified. After screening titles and abstracts, 48 studies were included, according to the eligibility criteria. A total of 56% and 42% of the studies were assessing treatments of UC or CD, respectively. Treatment options under evaluation included biological agents, mesalamine, immunosuppressants, and surgery. The majority of studies evaluated the cost-effectiveness of biological treatments. Biological therapies were dominant in 23% of the analyses and were cost-effective according to a $CAD50,000/QALY and $CAD100,000/QALY threshold in 41% and 62% of the analyses, respectively.

Conclusion: This literature review provided a comprehensive overview of the economic evaluations for the different treatment options for IBD over the past 12 years and represents a helpful reference for future economic evaluations.

Figures

Figure 1
Figure 1
Study flowchart.

References

    1. Romberg-Camps M. J. L., Bol Y., Dagnelie P. C., et al. Fatigue and health-related quality of life in inflammatory bowel disease: Results from a population-based study in the Netherlands: The IBD-South Limburg cohort. Inflammatory Bowel Diseases. 2010;16(12):2137–2147. doi: 10.1002/ibd.21285.
    1. Baumgart D. C., Sandborn W. J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet. 2007;369(9573):1641–1657. doi: 10.1016/S0140-6736(07)60751-X.
    1. Bernstein C. N., Fried M., Krabshuis J. H., et al. World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflammatory Bowel Diseases. 2010;16(1):112–124. doi: 10.1002/ibd.21048.
    1. Dudley-Brown S. Prevention of psychological distress in persons with inflammatory bowel disease. Issues in Mental Health Nursing. 2002;23(4):403–422. doi: 10.1080/01612840290052596.
    1. Berstein C., et al. Inflammatory Bowel Disease: A Global Perspective. 2009.
    1. Statistics Canada Health Statistics Division. Canadian Community Health Survey (CCHS) Cycle 4.1. Ottawa, Canada: Statistics Canada; 2008.
    1. Wlodarska M., Kostic A., Xavier R. An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host & Microbe. 2015;17(5):577–591. doi: 10.1016/j.chom.2015.04.008.
    1. Danese S., Sans M., Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Reviews. 2004;3(5):394–400. doi: 10.1016/j.autrev.2004.03.002.
    1. Loftus E. V., Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517. doi: 10.1053/j.gastro.2004.01.063.
    1. Molodecky N. A., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. quiz e30.
    1. The impact of inflammatory bowel disease in Canada 2012 - Final Report and Recommendations. 2012. .
    1. Drugs for inflammatory bowel disease. Treatment Guidelines from the Medical Letter. 2012;10(115):19–28.
    1. Crohn's Colitis Foundation of America, Inflammatory Bowel Diseases (IBD) Treatment Options Medications. 2015.
    1. Panaccione R., Fedorak R. N., Aumais G., et al. Canadian association of gastroenterology clinical practice guidelines: The use of infliximab in Crohn's disease. Canadian Journal of Gastroenterology & Hepatology. 2004;18(8):503–508. doi: 10.1155/2004/670161.
    1. Bressler B., et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–1058.
    1. Iskandar H. N., Dhere T., Farraye F. A. Ulcerative colitis: update on medical management. Current Fungal Infection Reports. 2015;17(11, article no. 44) doi: 10.1007/s11894-015-0466-9.
    1. Bitton A., Buie D., Enns R., et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. American Journal of Gastroenterology. 2012;107(2):179–194. doi: 10.1038/ajg.2011.386.
    1. Rocchi A., Benchimol E. I., Bernstein C. N., et al. Inflammatory bowel disease: a Canadian burden of illness review. Canadian Journal of Gastroenterology & Hepatology. 2012;26(11):811–817. doi: 10.1155/2012/984575.
    1. Ananthakrishnan A. N., Hur C., Juillerat P., Korzenik J. R. Strategies for the prevention of postoperative recurrence in crohn's disease: Results of a decision analysis. American Journal of Gastroenterology. 2011;106(11):2009–2017. doi: 10.1038/ajg.2011.237.
    1. Ananthakrishnan A. N., Korzenik J. R., Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflammatory Bowel Diseases. 2013;19(1):37–44. doi: 10.1002/ibd.22951.
    1. Blackhouse G., et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn's disease. Journal of Crohn's & Colitis. 2012;6(1):77–85. doi: 10.1016/j.crohns.2011.07.007.
    1. Bodger K., Kikuchi T., Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Alimentary Pharmacology & Therapeutics. 2009;30(3):265–274. doi: 10.1111/j.1365-2036.2009.04033.x.
    1. Doherty G. A., Miksad R. A., Cheifetz A. S., Moss A. C. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflammatory Bowel Diseases. 2012;18(9):1608–1616. doi: 10.1002/ibd.21904.
    1. Dretzke J., Edlin R., Round J., et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for crohn's disease. Health Technology Assessment. 2011;15(6):1–244. doi: 10.3310/hta15060.
    1. Jaisson-Hot I., Flourié B., Descos L., Colin C. Management for severe Crohn's disease: A lifetime cost-utility analysis. International Journal of Technology Assessment in Health Care. 2004;20(3):274–279. doi: 10.1017/S0266462304001084.
    1. Kaplan G. G., Hur C., Korzenik J., Sands B. E. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: A cost-effectiveness analysis. Alimentary Pharmacology & Therapeutics. 2007;26(11-12):1509–1520. doi: 10.1111/j.1365-2036.2007.03548.x.
    1. Lindsay J., Punekar Y. S., Morris J., Chung-Faye G. Health-economic analysis: Cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - Modelling outcomes in active luminal and fistulizing disease in adults. Alimentary Pharmacology & Therapeutics. 2008;28(1):76–87. doi: 10.1111/j.1365-2036.2008.03709.x.
    1. Punekar Y. S., Sunderland T., Hawkins N., Lindsay J. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value in Health. 2010;13(2):188–195. doi: 10.1111/j.1524-4733.2009.00658.x.
    1. Steenholdt C., Brynskov J., Thomsen O. Ø., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–927. doi: 10.1136/gutjnl-2013-305279.
    1. Steenholdt C., Brynskov J., Thomsen O. Ø., et al. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab. Digestive Diseases and Sciences. 2015;60(9):2762–2770. doi: 10.1007/s10620-015-3581-4.
    1. Tang D. H., Armstrong E. P., Lee J. K. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 2012;32(6):515–26.
    1. Velayos F. S., Kahn J. G., Sandborn W. J., Feagan B. G. A Test-based strategy is more cost effective than empiric dose escalation for patients with crohn's disease who lose responsiveness to infliximab. Clinical Gastroenterology and Hepatology. 2013;11(6):654–666. doi: 10.1016/j.cgh.2012.12.035.
    1. CADTH. Overview of CDR Clinical and Pharmacoeconomic Reports Adalimumab. Canadian Agency for Drugs and Technologies in Health; 2008.
    1. Loftus Jr E. V., et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. European Journal of Gastroenterology & Hepatology. 2009;21(11):1302–1309.
    1. Yu A. P., Johnson S., Wang S.-T., et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active crohns disease. PharmacoEconomics. 2009;27(7):609–621. doi: 10.2165/11312710-000000000-00000.
    1. Marchetti M., Liberato N. L., Di Sabatino A., Corazza G. R. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. European Journal of Health Economics. 2013;14(6):853–861. doi: 10.1007/s10198-012-0430-7.
    1. Saito S., Shimizu U., Nan Z., et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis. Journal of Crohn's and Colitis. 2013;7(2):167–174. doi: 10.1016/j.crohns.2012.04.007.
    1. Ananthakrishnan A. N., Hur C., Korzenik J. R. Certolizumab pegol compared to natalizumab in patients with moderate to severe crohn's disease: Results of a decision analysis. Digestive Diseases and Sciences. 2012;57(2):472–480. doi: 10.1007/s10620-011-1896-3.
    1. Priest V. L., Begg E. J., Gardiner S. J., et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. PharmacoEconomics. 2006;24(8):767–781. doi: 10.2165/00019053-200624080-00004.
    1. Archer R., Tappenden P., Ren S., et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (Including a review of TA140 and TA262): Clinical effectiveness systematic review and economic model. Health Technology Assessment. 2016;20(39) doi: 10.3310/hta20390.
    1. Chaudhary M. A., Fan T. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biologics in Therapy. 2013;3(1):45–60. doi: 10.1007/s13554-012-0007-0.
    1. Hyde C., Bryan S., Juarez-Garcia A., Andronis L., Fry-Smith A. Infliximab for the treatment of ulcerative colitis. Health Technology Assessment. 2009;13(Suppl 3) doi: 10.3310/hta13suppl3/02.
    1. Punekar Y. S., Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. European Journal of Health Economics. 2010;11(1):67–76. doi: 10.1007/s10198-009-0199-5.
    1. Stawowczyk E., Kawalec P., Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy. 2016;36(5):472–481. doi: 10.1002/phar.1742.
    1. Thorlund K., Druyts E., Mills E. Golimumab (Simponi) (Subcutaneous Injection): Adult Patients with Moderately to Severely Active Ulcerative Colitis Who Have Had an Inadequate Response to, or Have Medical Contraindications for, Conventional Therapies. Ottawa, Canada: 2014.
    1. Toor K., Druyts E., Jansen J. P., Thorlund K. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. Journal of Medical Economics. 2015;18(6):437–446. doi: 10.3111/13696998.2015.1012513.
    1. Tsai H. H., Punekar Y. S., Morris J., Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2008;28(10):1230–1239. doi: 10.1111/j.1365-2036.2008.03839.x.
    1. Ung V., et al. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. Clinical Gastroenterology & Hepatology. 2014;12(11, p. 1871-8.e8)
    1. Williams J. G., Alam M. F., Alrubaiy L., et al. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Pragmatic randomised trial and economic evaluation (CONSTRUCT) Health Technology Assessment. 2016;20(44):1–322. doi: 10.3310/hta20440.
    1. Yokomizo L., Limketkai B., Park K. T. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterology. 2016;3(1):p. e000093. doi: 10.1136/bmjgast-2016-000093.
    1. Xie F., Blackhouse G., Assasi N., Gaebel K., Robertson D., Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation. 2009;7, article no. 20 doi: 10.1186/1478-7547-7-20.
    1. Essat M., Tappenden P., Ren S., et al. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 2016;34(3):245–257. doi: 10.1007/s40273-015-0334-3.
    1. Brereton N., Bodger K., Kamm M. A., Hodgkins P., Yan S., Akehurst R. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics. 2010;13(1):148–161. doi: 10.3111/13696990903562861.
    1. Buckland A., Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2008;28(11-12):1287–1296. doi: 10.1111/j.1365-2036.2008.03856.x.
    1. Connolly M. P., Nielsen S. K., Currie C. J., Marteau P., Probert C. S. J., Travis S. P. L. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. Journal of Crohn's and Colitis. 2009;3(3):168–174. doi: 10.1016/j.crohns.2009.02.005.
    1. Connolly M. P., Nielsen S. K., Currie C. J., Poole C. D., Travis S. P. L. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. Journal of Crohn's and Colitis. 2009;3(1):32–37. doi: 10.1016/j.crohns.2008.10.004.
    1. Connolly M. P., Boersma C., Oldenburg B. The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands. The Netherlands Journal of Medicine. 2012;70(6):272–277.
    1. Connolly M. P., Kuyvenhoven J. P., Postma M. J., Nielsen S. K. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing. Journal of Crohn's and Colitis. 2014;8(5):357–362. doi: 10.1016/j.crohns.2013.09.015.
    1. Mackowiak J. I. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Managed Care Interface. 2006;19(10):39–56.
    1. Nishikawa A. M., Paladini L., Delfini R., Kotze P. G., Clark O. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa ® mesalazine 2 g sachet. Arquivos de Gastroenterologia. 2013;50(4):297–303. doi: 10.1590/S0004-28032013000400011.
    1. Prenzler A., Yen L., Mittendorf T., Von Der Schulenburg J.-M. Cost effectiveness of ulcerative colitis treatment in Germany: A comparison of two oral formulations of mesalazine. BMC Health Services Research. 2011;11, article no. 157 doi: 10.1186/1472-6963-11-157.
    1. Saini S. D., Waljee A. K., Higgins P. D. R. Cost Utility of Inflammation-Targeted Therapy for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2012;10(10):1143–1151. doi: 10.1016/j.cgh.2012.05.003.
    1. Yen E. F., Kane S. V., Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. American Journal of Gastroenterology. 2008;103(12):3094–3105. doi: 10.1111/j.1572-0241.2008.02130.x.
    1. Park K. T., Tsai R., Perez F., Cipriano L. E., Bass D., Garber A. M. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. Annals of Surgery. 2012;256(1):117–124. doi: 10.1097/SLA.0b013e3182445321.
    1. Swenson B. R., Hollenbeak C. S., Poritz L. S., Koltun W. A. Modified two-stage ileal pouch-anal anastomosis: Equivalent outcomes with less resource utilization. Diseases of the Colon & Rectum. 2005;48(2):256–261. doi: 10.1007/s10350-004-0848-9.
    1. Panes J., et al. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Digestive & Liver Disease. 2007;39(7):617–25. doi: 10.1016/j.dld.2007.03.007.
    1. Higgings J. P. T., Green S., editors. The Cochrane Collaboration. Chapter 5 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.
    1. Statistics Canada. Consulmer Price Index, Health Care: CANSIM Table 326-0020. 2013.
    1. Di Sabatino A., Liberato L., Marchetti M., Biancheri P., Corazza G. R. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Internal and Emergency Medicine. 2011;6(S1):17–27. doi: 10.1007/s11739-011-0673-9.
    1. Fleurence R., Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: Structured review of the literature. The Journal of Rheumatology. 2006;33(11):2124–2131.
    1. Huoponen S., Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 2015;10(12) doi: 10.1371/journal.pone.0145087.e0145087
    1. Marchetti M., Liberato N. L. Biological therapies in Crohn's disease: Are they cost-effective? A critical appraisal of model-based analyses. Expert Review of Pharmacoeconomics & Outcomes Research. 2014;14(6):815–824. doi: 10.1586/14737167.2014.957682.
    1. Martelli L., Olivera P., Roblin X., Attar A., Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. Journal of Gastroenterology. 2016;52(1):19–25.
    1. Smart C., Selinger C. P. The cost-effectiveness of infliximab in Crohn's disease. Expert Review of Pharmacoeconomics & Outcomes Research. 2014;14(5):589–598. doi: 10.1586/14737167.2014.950235.
    1. Tang D. H., Harrington A. R., Lee J. K., Lin M., Armstrong E. P. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflammatory Bowel Diseases. 2013;19(12):2673–2694. doi: 10.1097/MIB.0b013e3182916046.
    1. Assasi N., et al. Anti-TNF-α drugs for refractory inflammatory bowel disease: Clinical- and cost-effectiveness analyses [Technology report number 120] Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2009.
    1. Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. PharmacoEconomics. 2011;29(5):387–401. doi: 10.2165/11584820-000000000-00000.
    1. Park K. T., Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflammatory Bowel Diseases. 2011;17(7):1603–1609. doi: 10.1002/ibd.21488.
    1. Beaugerie L., Itzkowitz S. H. Cancers Complicating Inflammatory Bowel Disease. The New England Journal of Medicine. 2015;373(2):p. 195. doi: 10.1056/NEJMc1505689.
    1. Kappelman M. D., Farkas D. K., Long M. D., et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clinical Gastroenterology and Hepatology. 2014;12(2):265.e1–273.e1. doi: 10.1016/j.cgh.2013.03.034.
    1. Binion D. G., Louis E., Oldenburg B., et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: A meta-analysis. Canadian Journal of Gastroenterology & Hepatology. 2011;25(9):492–496. doi: 10.1155/2011/938194.
    1. van der Valk M. E., Mangen M. J., Siersema P. D., van Oijen M. G., Oldenburg B. Sa1283 Productivity Losses in Inflammatory Bowel Disease: A Systematic Review. Gastroenterology. 2012;142(5):p. S-262. doi: 10.1016/S0016-5085(12)60990-1.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj